The Department of War must maintain an integrated Military Health System pharmacy benefits program and uses its Pharmacy and Therapeutics Committee to evaluate therapeutic-class agents for clinical and cost effectiveness in recommending Uniform Formulary placement and cost-sharing classifications. An RFQ has been issued for pharmaceutical agents in drug classes being considered for UF placement, and the Defense Health Agency may award UF Blanket Purchase Agreements and Additional Discount Program Agreements based on the UF decision. The February 2027 committee review will cover ophthalmic dry-eye products and oral testosterone replacement therapies. A pre-quotation teleconference is scheduled for November 17, 2026. Instructions and points of contact are provided in the attached RFQ.